Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,024 across all filing types
Latest filing 2026-06-08 Capital/Financing Update
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 85% confidence The document is a Form 8-K Current Report filed under Item 8.01 ‘Other Events’ announcing the sale of 3,509,604 shares at $1.279 under the company’s At-The-Market offering agreement. This is a financing activity/update regarding capital structure (fundraising via share issuance), which corresponds to the Capital/Financing Update category (CAP).
2026-06-08 English
FORM 8-K
Regulatory Filings Classification · 80% confidence The document is a Form 8-K "Current Report" filed under the Securities Exchange Act of 1934, detailing a press release in Item 7.01 regarding Regulation FD Disclosure. It’s a regulatory announcement rather than a financial report, earnings release, or management presentation. Therefore it falls into the general Regulatory Filings category (RNS).
2026-06-05 English
FORM 8-K
Regulatory Filings Classification · 85% confidence The document is a United States SEC Form 8-K “Current Report” dated May 28, 2026, detailing a Regulation FD disclosure and press release concerning PMDA consultation for a therapy. It is not an earnings release, annual or interim report, nor an M&A or director deal. It is a general regulatory filing (8-K) and thus falls under the fallback category “Regulatory Filings (RNS).”
2026-05-28 English
FORM 8-K
Regulatory Filings Classification · 85% confidence The document is a Form 8-K current report filed with the SEC (Item 7.01, Regulation FD Disclosure). It is a regulatory filing announcing the issuance of a press release and furnishing exhibit information, without providing substantive financial statements or investor presentations. This aligns with the general “Regulatory Filings” category (RNS) for miscellaneous SEC filings and announcements.
2026-05-21 English
FORM 8-K
Earnings Release Classification · 92% confidence The document is a Form 8-K “Current Report” filed under Item 2.02 “Results of Operations and Financial Condition,” which is the SEC mechanism for furnishing an earnings press release announcing quarterly results. It specifically states that a press release for the quarter ended March 31, 2026 is furnished as Exhibit 99.1. This matches the definition of an Earnings Release (ER), the initial announcement of periodical financial results. Q1 2026
2026-05-15 English
FORM 10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.